← Back to Search

Topoisomerase I inhibitor

AR-67 for Glioblastoma

Phase 2
Waitlist Available
Led By James J Vredneburgh, MD
Research Sponsored by Arno Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred after treatment bevacizumab (including patients who've received temazolamide, but no bevacizumab). The primary objective in the rapid bevacizumab failure group (< 90 days) is to determine the 2-month PFS.

Eligible Conditions
  • Glioblastoma
  • Gliosarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the 6-month Progression free survival (PFS) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred after treatment bevacizumab.
The primary objective in the rapid bevacizumab failure group (< 90 days) is to determine the 2-month PFS.
Secondary outcome measures
the effect of AR-67 on event-free survival (EFS)
the effect of AR-67 on overall PFS
the effect of AR-67 on overall survival (OS)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AR-67Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Arno TherapeuticsLead Sponsor
7 Previous Clinical Trials
268 Total Patients Enrolled
James J Vredneburgh, MDPrincipal InvestigatorDuke University Medical Center - The Preston Robert Tisch Brain Tumor Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
2009. "Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01124539.
All > Osa
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top